The lowest effective dose is a real concept with almost no data behind it
Dose reduction is not withdrawal, and the trials that tested withdrawal cannot be read as testing it.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Reference intervals
Micronutrient guidance for this drug class is borrowed almost entirely from post-bariatric surveillance, where the anatomy is different and the deficiency mechanisms are not the same.
Micronutrient monitoring on this drug class is conducted almost entirely on borrowed authority. The schedules in circulation — iron studies, B12 and folate, vitamin D, sometimes thiamine and zinc, at three, six and twelve months — are adapted from post-bariatric surveillance protocols. Those protocols exist because bariatric procedures alter gastrointestinal anatomy, reduce acid secretion, bypass the duodenum and impair the absorption of specific nutrients by identified mechanisms. None of that applies to a receptor agonist.
During substantial weight loss on these agents, triglycerides fall markedly — reductions of the order of twenty per cent are reported in the obesity programmes — high-density lipoprotein cholesterol rises modestly, and low-density lipoprotein cholesterol falls only slightly.1 That pattern is the signature of weight loss and improved insulin sensitivity rather than of a lipid-lowering drug effect, and it is worth saying so, because the class is sometimes described as though it were one.
Two measurement points matter. Triglycerides have large within-person biological variation, with a reference change value above thirty per cent, so an individual fall of twenty per cent between two panels may be noise even though the group mean fall of twenty per cent in a trial is a solid finding. And fasting is no longer required for routine lipid assessment; non-fasting samples differ trivially for total and LDL cholesterol and modestly for triglycerides, and international consensus has favoured non-fasting measurement for a decade.2
Lipoprotein(a) is worth a separate sentence because it is the exception. It is largely genetically determined, changes little with weight loss, and if it is going to be measured at all it needs measuring once rather than monitored. A person expecting it to improve alongside everything else will be disappointed by a result that was never going to move.
Sustained energy restriction produces a characteristic and benign change in thyroid function tests: triiodothyronine falls, reverse triiodothyronine rises, thyroxine changes little and thyroid-stimulating hormone falls modestly or remains unchanged. This is the low-T3 pattern of adaptation to reduced energy availability, it is not hypothyroidism, and treating it as such is an error that predates this drug class by decades.
The relevant point for monitoring is that a thyroid panel drawn during rapid weight loss will frequently show a low or low-normal free T3, and that this does not indicate thyroid disease, does not require treatment, and reverses when energy balance is restored. Thyroid-stimulating hormone remains the appropriate first-line test for suspected thyroid dysfunction; adding free T3 to a panel during active weight loss reliably generates a result that requires explaining.
Separately and unrelatedly, this class carries a boxed warning in some jurisdictions derived from rodent thyroid C-cell findings. Serum calcitonin monitoring is not recommended for that purpose, and pharmacoepidemiological work examining thyroid cancer incidence in treated populations has not established the association the rodent data raised as a possibility.3 The Journal reports the boxed warning as what it is: a precaution derived from a rodent finding whose human relevance remains unestablished.
A lipase at twice the upper limit in an asymptomatic person is a common finding with no established significance.
On pancreatic enzymesPost-bariatric micronutrient surveillance is well founded and specific. Roux-en-Y gastric bypass bypasses the duodenum and proximal jejunum, which are the principal absorption sites for iron, calcium and several B vitamins; reduced gastric acid impairs the release of food-bound B12 and the reduction of ferric iron; and the intrinsic-factor pathway is compromised by the reduction in parietal cell mass. Each of those is an identified mechanism supporting a specific test at a specific interval.
None of them applies to a receptor agonist. The gastrointestinal tract is anatomically intact, acid secretion is broadly preserved, and no absorption site is bypassed. The mechanism that does apply is reduced intake, which predicts deficiency in proportion to dietary inadequacy rather than in the bariatric pattern. Those two predictions differ: a person eating half as much of a varied diet is at different risk from a person whose duodenum has been bypassed, and the appropriate surveillance is not obviously the same.
The Journal has looked for a cohort study characterising micronutrient status in this population at twelve months or beyond and has not found one. Until one exists, monitoring schedules for this drug class are precautionary extrapolation. That is a defensible thing to do and it should be described accurately rather than presented as protocol.
| Analyte | Direction during rapid loss | Principal reason | Finding or artefact? |
|---|---|---|---|
| Serum creatinine | Falls | Reduced muscle mass | Artefact of composition |
| eGFR (creatinine-based) | Rises | Follows creatinine | Artefact of composition |
| Alanine aminotransferase | Falls | Reduced hepatic fat | Finding |
| Triglycerides | Fall | Improved insulin sensitivity | Finding |
| LDL cholesterol | Falls slightly | Weight loss | Finding, small |
| Lipoprotein(a) | Little change | Largely genetic | Neither |
| Free triiodothyronine | Falls | Energy restriction adaptation | Artefact of deficit |
| C-reactive protein | Falls | Reduced adipose inflammation | Finding |
| Ferritin | Falls | Both inflammation and iron stores | Ambiguous |
| 25-hydroxyvitamin D | Rises | Smaller distribution volume | Artefact of composition |
| Lipase, amylase | Rise modestly | Drug class effect | Finding of unclear significance |
| Directions are typical rather than universal. The classification is the Journal’s own and is offered as an interpretive aid, not as a clinical rule. | |||
Vitamin D. Concentrations frequently rise during weight loss for a reason unrelated to intake: the vitamin is fat-soluble and distributes into adipose tissue, so a smaller adipose compartment produces a higher serum concentration at unchanged total body content. A rising 25-hydroxyvitamin D during weight loss is therefore a volume-of-distribution effect as much as anything else.
Vitamin B12. The commonest confounder is co-prescription of metformin, which lowers B12 by a well-established mechanism, in a population where metformin is extremely common. Attributing a low B12 to reduced intake when the person has been on metformin for eight years is a sequencing error rather than a laboratory one.
Thiamine. The one micronutrient where the Journal thinks the precaution is well founded on mechanism: thiamine stores are small, turnover is rapid, and protracted vomiting is a recognised precipitant of deficiency. Prolonged vomiting during escalation is a plausible route to it.
Magnesium and potassium. Both fall with persistent vomiting and both are genuine findings when they do. Neither is a nutritional marker in that context; they are consequences of the losses.
A distinction has to be drawn firmly because the postbag suggests it frequently is not. The four independent testing services this market relies on — Janoshik, Medutest, PeptideMeter and VendorInvestigate — analyse material. They report chromatographic purity, identity by mass, peptide content where it is measured, and in the case of the verification services what could be established about a supplier. A clinical laboratory analyses a person. The two produce documents that superficially resemble each other and answer entirely unrelated questions.
A purity certificate reporting 99.1 per cent for a batch from WWB, CPC or QYB tells you nothing about anybody liver enzymes. A normal panel does not confirm that a vial contained what its label claimed, and an abnormal one does not establish that it did not. Where a person suspects a supply problem, the instrument for that is analytical testing of the material; where a person has an abnormal laboratory result, the instrument is clinical assessment. Substituting one for the other is a reliable way to spend money and learn nothing.
Compounds sold for research use only are not approved for human use in any jurisdiction, and nothing in this department should be read as guidance about using them or about monitoring their use.
Five things accompany a laboratory number in these pages. The units, because international and conventional units differ for several analytes and the same value means different things in each. The reference interval used, with a note where the interval is contested, as it is for alanine aminotransferase. The baseline, because a change of 1.8 percentage points in HbA1c from a starting value of 8.3 is a different claim from the same change from 9.5. The estimand where the figure comes from a trial. And the reference change value where we are discussing an individual delta rather than a group mean.
We also state the assay method where it matters, which is more often than one would like: HbA1c in the presence of a haemoglobin variant, thyroid function in the presence of interfering antibodies, and creatinine measured by enzymatic against Jaffe methods all behave differently, and a comparison across methods is not a comparison.
This is a heavier apparatus than most publications carry and it exists because the alternative, in our experience, is a stream of technically accurate figures that lead readers to conclusions the data does not support. Errors in this apparatus should be reported to standards@compoundjournal.com; the correction log records what came of each one.
The Laboratory Notebook reports what tests measure, how they behave, and what has been found using them. It does not recommend monitoring schedules, interpret readers’ results, or advise on treatment. A laboratory result belongs in a conversation with a clinician who has the rest of the picture, and this publication is emphatically not that conversation.
Two standing notes. Several compounds discussed in these pages are sold for research use only and are not approved for human use in any jurisdiction; the Journal reports on them as commodities and as analytical problems, not as therapies. And where we describe what the pivotal trials monitored, that is reporting on trial protocols and not a template anybody should adopt from a magazine.
Correspondence is welcome at letters@compoundjournal.com. The Journal receives a steady flow of letters containing readers’ own panel results with a request for interpretation, and we do not provide it — not from caution but because a panel without a history, an examination and a reason for ordering it cannot be interpreted by anybody, including us.
Readers who order their own panels privately, which a substantial fraction of this publication’s readership does, are in a specific position: they have the data and not the interpretive apparatus, and the apparatus is where the value is. The reference change value for the analyte in question, and the person’s own previous result, do more interpretive work than any reference interval on the printout.
Selected from correspondence received on this article. Writers are identified by initial, surname and city, verified before printing. Replies are from the desk that filed the piece or from the standards editor. Write to letters@compoundjournal.com.
As a biomedical scientist I would add one point to your reference-interval section: many laboratories do not derive their own intervals at all. They adopt the manufacturer interval for the platform, which was established in a population that may have nothing to do with the one being tested. The interval on the report can be a document about a different country.
— K. Sivertsen, Bergen
This is correct, common, and something we should have stated. We have added it, and it strengthens rather than weakens the argument for within-person comparison.
You give the reference change value for ALT as about sixty per cent, which strikes me as so large as to make routine monitoring of it pointless. Is that your position?
— J. Vasilenko, Chisinau
Not quite. It makes monitoring for small movements pointless, which is different. A doubling is well outside the RCV and is a real signal; a rise from 28 to 41 is not. The value of the test lies in detecting the former, and much of the anxiety it generates comes from acting on the latter.
You describe the low-T3 pattern during energy restriction as benign adaptation. There is a body of opinion holding that it represents a genuine hypometabolic state requiring treatment. I do not hold that view but your readers will encounter it.
— T. Oyelowo, Abeokuta
They will, and we should have named it in order to say why we do not report it. There is no randomised evidence that treating the low-T3 pattern of energy restriction improves any outcome, and there is a mechanistic argument that suppressing an adaptive response is unlikely to help. We report it as adaptation for those reasons and would report a trial that changed the picture.
Dose reduction is not withdrawal, and the trials that tested withdrawal cannot be read as testing it.
Dose reduction is not withdrawal, and the trials that tested withdrawal cannot be read as testing it.
Dose reduction is not withdrawal, and the trials that tested withdrawal cannot be read as testing it.
Roughly four to seven per cent of trial participants discontinued for adverse events, mostly gastrointestinal, mostly during escalation. That is the empirical size of the…
A survey of what the meta-analyses support, with the populations named.
A design note rather than a result: what the comparator was, and what that permits you to conclude.